/wp-content/uploads/logo.png
0
0
Emily Hennes
/wp-content/uploads/logo.png
Emily Hennes2023-10-24 13:15:092023-11-01 12:26:23Endeavor BioMedicines Appoints Paul Frohna, M.D., Ph.D., as Chief Medical Officer
/wp-content/uploads/logo.png
0
0
Emily Hennes
/wp-content/uploads/logo.png
Emily Hennes2023-10-17 10:10:442023-10-18 12:35:53Endeavor BioMedicines Enters License Agreement with Hummingbird Bioscience for Worldwide Rights to HMBD-501, a Next Generation HER3-Targeted Antibody-Drug Conjugate (ADC)
/wp-content/uploads/logo.png
0
0
eallison
/wp-content/uploads/logo.png
eallison2023-09-01 14:27:362023-09-01 14:40:58Endeavor BioMedicines Completes Enrollment in Phase 2a Clinical Trial of ENV-101 (Taladegib) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
/wp-content/uploads/logo.png
0
0
David Anderson
/wp-content/uploads/logo.png
David Anderson2022-02-07 05:05:122022-02-10 08:50:07Endeavor BioMedicines Closes $101M Series B Financing to Advance Clinical-Stage Precision Medicine Pipeline
/wp-content/uploads/logo.png
0
0
Emily Hennes
/wp-content/uploads/logo.png
Emily Hennes2022-01-19 14:48:512022-02-03 18:59:03Endeavor Biomedicines doses first patient in phase 2 clinical trial of Taladegib (ENV-101) for idiopathic pulmonary fibrosis; appoints chief medical officer
/wp-content/uploads/logo.png
0
0
Emily Hennes
/wp-content/uploads/logo.png
Emily Hennes2022-01-19 15:01:212023-10-13 10:57:28Endeavor Biomedicines Launches With $62 Million Series A Financing And Mission To Reverse The Course Of Devastating Pulmonary Disease
Scroll to top
